Skip to main content

Table 5 Analysis of the risk factors of microbiological improvement evaluated with MAC cultures

From: Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease

Variables Total Sputum conversion Sputum positive Multivariate analysis
n (n = 12) (n = 21) Odds ratio
Continuation of CAM or AZM 26 10 (83) 16 (76) 1.1 (0.13–8.7)
Treatment with 3 or more drugs 21 6 (50) 15 (71) 0.57 (0.092–3.5)
Age ≥75 years* 8 6 (50) 2 (9.5) 5.7 (0.67–49)
Female 31 10 (83) 21 (100)  
Nonsmoker 30 11 (92) 19 (90)  
BMI 18 kg/m2 11 5 (42) 6 (29)  
NB (radiological findings) 27 9 (75) 18 (86)  
Total lesion extenta 1 or 2 26 9 (75) 17 (81)  
Cavity 25 10 (83) 15 (71)  
Albumin ≥3.5 g/dl 26 11 (92) 15 (71) 3.0 (0.22–41)
CRP <1.0 mg/dl 16 5 (42) 11 (52) 0.79 (0.12–5.2)
  1. Data are presented as no. (%)
  2. CAM clarithromycin, AZM azithromycin, NB nodular/bronchiectatic disease, BMI body mass index, CRP C-reactive protein
  3. *Significant at p < 0.05 in univariate analysis
  4. a1 within one third of unilateral lung field; 2 within unilateral lung field